论文部分内容阅读
肺癌是全球病死率最高的恶性肿瘤,晚期肺癌生存率更低.目前对于无驱动基因突变的肺癌,标准治疗方案为化疗,但疗效欠佳,生存获益低,对于有驱动基因突变的肺癌患者,分子靶向治疗可适当延长生存期,但最终大部分患者会出现耐药,因此目前急需新的方案治疗晚期非小细胞肺癌(NSCLC).血管生成在肿瘤的生长、转移过程中发挥重要作用,促进新生异常血管网形成、导致肿瘤微环境发生改变.目前贝伐珠单抗是迄今为止唯一一个在NSCLC一线治疗中与化疗药物联合提高生存获益的抗血管生成药物.近年来,一些新的抗血管生成药物被证明在NSCLC中有生存获益.“,”Lung cancer is the leading cause of death from cancer worldwide with limited available treatment options in absence of specific molecular alteration.For lung cancer without driving gene mutation,the standard treatment is chemotherapy,but the efficacy is poor,and the survival benefit is low;for patients with lung cancer with driving gene mutations,molecular targeted therapy may prolong the survival,but in the end,most of the patients will develop drug resistance,so there is an urgent need for new treatment of advanced non-small cell lung cancer(NSCLC).Angiogenesis phys a central role in the tumor growth and metastatic dissemination which stimulates multiple cells to build new abnormal microvessels and leads to tumor microenvironment alterations.To date,bevacizumab is the only angiogenesis inhibitor that has been approved for the treatment of patients with advanced NSCLC in first-line setting.Moreover,in the last few years,some new antiangiogenic agents have been proved beneficial for the treatment of patients with advanced NSCLC.